Alzinova: Freezing out AD

Alzinova Alzheimer's vaccine targets highly toxic oligomer form of beta amyloid

Alzinova AB is developing an Alzheimer's disease vaccine that uses an engineered beta amyloid mimic to raise an immune response against highly toxic AD-associated beta amyloid oligomers. The approach could yield a more potent protective immune response than prior vaccines aimed at larger fibrillar aggregates of beta amyloid.

Most therapeutic efforts in AD have focused on blocking the production or accumulation of beta amyloid, which over time leads to neurodegeneration and dementia.

The foremost strategy for blocking beta amyloid has

Read the full 787 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE